Stage II/III Colorectal Cancer Recurrence
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak jelita grubego w stadium II (wysokiego ryzyka) lub III.
- •Pacjent przeszedł standardowe badania diagnostyczne i leczenie raka.
- •Pacjent przeszedł operację usunięcia guza rakowego i następnie chemioterapię.
- •Potwierdzono brak raka w momencie włączania do badania.
✗ Disqualifies
- •Brak pisemnej zgody na udział w badaniu.
- •Nawrót raka w ciągu pierwszych 6 miesięcy po zakończeniu chemioterapii.
- •Dziedziczne zespoły predysponujące do raka jelita grubego (stwierdzone badaniami genetycznymi).
- •Choroby zapalne jelit.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
City of Hope Medical Center
Monrovia, United States
Second Affiliated Hospital of Dalian Medical University
Dalian, China
Barcelona University
Barcelona, Spain
La Paz University Hospital
Madrid, Spain
Trial contact
Ajay Goel, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.